Dogwood Therapeutics SEC Filings

Dogwood Therapeutics, Inc. filed its Form 10-Q reporting first-quarter 2026 results as a pre-revenue, development-stage biopharmaceutical company focused on cancer pain and neuropathy. The company posted a net loss of $4,986,614 for the three months ended March 31, 2026, narrowing from $10,924,952 a year earlier, as total operating expenses were $5,076,366.

Cash and cash equivalents increased to $13,227,839 at March 31, 2026 from $6,524,744 at year-end 2025, helped by net proceeds of about $11.4M from a January 2026 equity and warrant financing. The accumulated deficit reached $113,062,930, and management states that existing cash will not fund operations for at least 12 months, indicating substantial doubt about the company’s ability to continue as a going concern without additional financing.

Dogwood Therapeutics reported first quarter 2026 results, highlighting pipeline progress and stronger finances. The company recorded no revenue, with research and development expenses of $2.7 million and general and administrative expenses of $2.4 million, both modestly higher than a year earlier.

Net loss attributable to common stockholders narrowed to $5.0 million, or $0.15 per share, from $12.2 million, or $8.45 per share, in the first quarter of 2025. Cash and cash equivalents increased to $13.2 million as of March 31, 2026.

Operationally, Halneuron® remains on track for Phase 2b top-line data in chemotherapy-induced neuropathy in fall 2026, and SP16 advanced with FDA acceptance of its investigational new drug application and planned Phase 1b development. Dogwood also announced a worldwide development and commercialization partnership for legacy antiviral assets with potential value up to $100 million for the company and its current and former shareholders.

Dogwood Therapeutics, Inc. is asking stockholders to vote at a virtual annual meeting on June 16, 2026. The ballot includes electing seven directors, ratifying Forvis Mazars, LLP as auditor, and advisory Say‑on‑Pay and Say‑on‑Frequency votes.

A key item is a proposal to amend the Certificate of Incorporation to increase authorized common stock from 43,000,000 to 195,000,000 shares and preferred stock from 2,000,000 to 5,000,000 shares, giving the company more flexibility for financing and equity incentives. As of April 26, 2026, 33,401,553 common shares were outstanding. Sealbond Limited beneficially owns 21,822,333 shares, or 65.3%, and Conjoint, Inc. owns 2,842,638 shares, or 8.5%.

The proxy details board structure, committee independence, and executive pay. In 2025, CEO Greg Duncan received total compensation of $3,344,728, while other named executives also received salary, cash bonuses and significant option awards under the company’s 2020 Equity Incentive Plan, which authorizes up to 2,972,787 shares for equity grants.

Dogwood Therapeutics, Inc. is soliciting proxies for its 2026 virtual Annual Meeting on June 16, 2026 to elect seven directors, ratify Forvis Mazars, LLP as auditor, approve an amendment to increase authorized common stock from 43,000,000 to 195,000,000 shares and preferred from 2,000,000 to 5,000,000 shares, and conduct advisory votes on compensation frequency and pay. The Board recommends voting FOR all proposals. The record date for voting is April 21, 2026. The proxy materials and the 2025 Annual Report are available at the Company’s investor website.

Dogwood Therapeutics filed a Form 8-K to furnish a shareholder letter providing a first quarter 2026 corporate update. The company is a development-stage biopharmaceutical business focused on new non-opioid medicines to treat pain and neuropathic disorders, especially cancer- and chemotherapy-induced neuropathic pain.

Dogwood highlights two first-in-class candidates, Halneuron and SP16 IV. Halneuron is in Phase 2b development for pain conditions including chemotherapy-induced neuropathic pain and has FDA fast track designation for CINP. SP16 IV, an LRP1 agonist, has shown preclinical anti-inflammatory and potential nerve-repair effects, with a forthcoming Phase 1b CINP trial fully funded by the National Cancer Institute.

Dogwood Therapeutics, Inc. filed its annual report detailing a pre-revenue, development-stage biopharmaceutical business focused on non-opioid pain and neuropathy treatments. The lead asset, Halneuron, a tetrodotoxin-based Nav1.7 modulator, is in a U.S. Phase 2b trial for chemotherapy-induced neuropathic pain, with top-line data expected in the third quarter of 2026.

The company is also advancing SP16, a licensed serpin-derived peptide program backed by a National Cancer Institute grant, with Phase 1b enrollment projected to start in mid‑2026, and maintains partnered antiviral programs IMC‑1 and IMC‑2 for fibromyalgia and Long‑COVID. Dogwood reports substantial net losses, an accumulated deficit over $108 million and a going-concern warning, and notes that its cash balance plus recent equity raises fund current trials but will not support long-term needs without additional capital.

Dogwood Therapeutics reported fourth quarter and full year 2025 results, highlighting increased investment in its pain and neuropathy pipeline and a longer cash runway. For Q4 2025, research and development expenses were $2.3 million, roughly flat year over year, while general and administrative expenses fell to $1.5 million from $5.2 million, mainly as prior transaction costs rolled off. Quarterly net loss attributable to common stockholders narrowed to $3.8 million, or $0.26 per share, from $8.2 million, or $6.29 per share.

For full year 2025, research and development expenses rose to $21.8 million from $3.5 million, driven by $12.0 million of acquired in-process R&D for SP16, higher Halneuron® Phase 2b clinical trial costs, and manufacturing and personnel spending. General and administrative expenses decreased to $6.1 million from $8.7 million, reflecting lower nonrecurring transaction and public company costs, partially offset by higher salaries, legal and professional fees, and taxes. Net loss attributable to common stockholders grew to $35.5 million, or $7.13 per share, from $12.9 million, or $12.52 per share.

As of December 31, 2025, cash and cash equivalents were $6.5 million. The company expects this balance, together with $11.4 million of net proceeds received in January 2026, to fund operations through the Halneuron® Phase 2b final data readout and into the fourth quarter of 2026. Dogwood’s pipeline centers on Halneuron®, a fast track–designated, non-opioid NaV 1.7 analgesic in Phase 2b for chemotherapy-induced neuropathic pain, and SP16 IV, an LRP1 agonist for neuropathy with a forthcoming, National Cancer Institute–funded Phase 1b CINP trial.

Dogwood Therapeutics, Inc. reported that shareholders approved the potential exercise of an unregistered common stock warrant to purchase up to 4,386,037 shares of common stock under a January 11, 2026 Securities Purchase Agreement and Nasdaq Listing Rule 5635(d).

At the Special Meeting, 29,310,309 common shares were represented, equal to 88.03% of the voting power as of the February 12, 2026 record date, establishing a quorum. The warrant exercise proposal passed with 29,286,786 votes for, 19,057 against and 4,466 abstentions. Shareholders also approved a proposal permitting adjournment of the Special Meeting if necessary, with 29,283,790 votes for, 21,571 against and 4,948 abstentions.